I'd like to see a combination of the two. PPS stops BME and halts or slows Cartilage degradation while past stem cell therapies seem to have targeted cartilage regrowth. What is interesting is that the exec at PAR are ex-MSB, where this drug and its interaction with stem cells was studied. With PPS fast becoming the standard of care for knee OA wouldn't it be nice if they could prove better efficacy in combination with stem cells.
W
- Forums
- ASX - By Stock
- Osteoarthrities paper
I'd like to see a combination of the two. PPS stops BME and...
Featured News
Add CYP (ASX) to my watchlist
(20min delay)
|
|||||
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.72M |
Open | High | Low | Value | Volume |
20.5¢ | 21.0¢ | 20.0¢ | $5.904K | 29.06K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 40051 | 20.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.0¢ | 141121 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 40051 | 0.205 |
3 | 98026 | 0.200 |
2 | 10187 | 0.195 |
4 | 49160 | 0.190 |
2 | 62017 | 0.185 |
Price($) | Vol. | No. |
---|---|---|
0.210 | 141121 | 2 |
0.215 | 2183 | 1 |
0.220 | 162191 | 6 |
0.230 | 15037 | 1 |
0.250 | 42019 | 2 |
Last trade - 14.58pm 29/04/2024 (20 minute delay) ? |
|
|||||
Last
21.0¢ |
  |
Change
0.000 ( 2.44 %) |
|||
Open | High | Low | Volume | ||
20.0¢ | 21.0¢ | 20.0¢ | 20062 | ||
Last updated 15.34pm 29/04/2024 ? |
Featured News
CYP (ASX) Chart |